Hospital
Medina Hospital
Medina Hospital was paid $8.03M by Medicaid between Jan 2018 and Dec 2024, across 208 billing codes. Its largest line is 99285, emergency room visit (most serious) — 16% of everything it billed.
33Billing provider infoMEDINA HOSPITAL
MEDINA, OH 44256
MEDINA, OH 44256
33aNPI1083696710assigned 11/17/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$8.03M
24GClaims236,415
24DCodes billed208
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Ohio
Rank by total paid#82 of 101
Median peer was paid$22.32M
This provider vs. median0.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LARAWAY, DENNIS controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 10,154 | $322K | |
| 2019 | 10,266 | $339K | |
| 2020 | 6,453 | $324K | |
| 2021 | 12,311 | $548K | |
| 2022 | 11,716 | $449K | |
| 2023 | 109,334 | $3.73M | |
| 2024incomplete | 76,181 | $2.32M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 16% | 11,240 | 9,440 | $1.32M |
| 96361 | Intravenous infusion, hydration; each additional hour | 15% | 3,993 | 2,567 | $1.23M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 7.0% | 5,099 | 4,366 | $566K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 6.3% | 7,951 | 3,144 | $504K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 5.7% | 4,240 | 3,889 | $458K |
| 70450 | Computed tomography, head or brain; without contrast material | 4.1% | 1,384 | 1,120 | $328K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.0% | 1,391 | 1,123 | $319K |
| A0429 | Emergency ambulance ride, basic life supportAmbulance service, basic life support, emergency transport (bls-emergency) | 3.0% | 2,534 | 2,188 | $244K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 2.5% | 1,964 | 1,625 | $200K |
| G0378 | Hospital observation service, per hour | 2.4% | 2,285 | 971 | $189K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | 2.2% | 295 | 213 | $181K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.2% | 1,473 | 1,076 | $176K |
196 more codes
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.2% | 714 | $175K |
| A0427 | Emergency ambulance ride, advanced life support | 2.0% | 1,376 | $165K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 2.0% | 1,093 | $164K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.7% | 781 | $136K |
| 80053 | Comprehensive metabolic panel | 1.4% | 16,378 | $111K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 1.1% | 496 | $91K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.0% | 1,192 | $83K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 704 | $69K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 106 | $69K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 570 | $66K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,140 | $61K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 534 | $58K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 167 | $43K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 506 | $40K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,841 | $31K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,069 | $29K |
| 93975 | <1% | 262 | $28K | |
| 82805 | <1% | 875 | $25K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 104 | $24K |
| 0002A | <1% | 587 | $22K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 14,471 | $22K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,011 | $22K |
| 0001A | <1% | 603 | $21K | |
| 95811 | <1% | 30 | $20K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,398 | $20K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,594 | $20K |
| 76642 | <1% | 185 | $19K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 20,387 | $19K |
| 71250 | <1% | 238 | $19K | |
| 97161 | <1% | 792 | $19K | |
| 11043 | <1% | 79 | $19K | |
| A0425 | Ground mileage, per statute mile | <1% | 4,268 | $19K |
| 76770 | <1% | 114 | $18K | |
| 73564 | <1% | 511 | $18K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 44 | $17K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 65 | $16K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 599 | $15K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 410 | $15K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 648 | $14K |
| 70498 | <1% | 42 | $14K | |
| 80061 | Lipid panel | <1% | 1,149 | $14K |
| 73030 | <1% | 494 | $14K | |
| 86850 | <1% | 685 | $14K | |
| 73630 | <1% | 576 | $13K | |
| 93017 | <1% | 147 | $13K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 624 | $13K |
| 85027 | <1% | 4,527 | $13K | |
| 73130 | <1% | 306 | $12K | |
| 84439 | <1% | 579 | $12K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 5,561 | $12K |
| 73502 | <1% | 385 | $11K | |
| J3490 | Unclassified drugs | <1% | 252 | $11K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 736 | $11K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 36 | $11K |
| 93971 | <1% | 122 | $10K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 755 | $10K |
| 76830 | Ultrasound, transvaginal | <1% | 213 | $9K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 458 | $9K |
| 93799 | <1% | 1,702 | $8K | |
| 96367 | <1% | 280 | $8K | |
| 82728 | <1% | 565 | $8K | |
| 87631 | <1% | 45 | $8K | |
| 97116 | <1% | 332 | $8K | |
| 86140 | <1% | 636 | $7K | |
| 86900 | <1% | 692 | $7K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 168 | $7K |
| 72100 | <1% | 257 | $7K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,012 | $7K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 232 | $7K |
| 83735 | <1% | 4,950 | $6K | |
| 82607 | <1% | 465 | $6K | |
| 73110 | <1% | 205 | $6K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 502 | $6K |
| 84484 | <1% | 4,034 | $6K | |
| 97165 | <1% | 175 | $6K | |
| 73610 | <1% | 354 | $6K | |
| 84702 | <1% | 776 | $6K | |
| 85610 | <1% | 2,315 | $5K | |
| 83540 | <1% | 624 | $5K | |
| 76857 | <1% | 81 | $5K | |
| 71045 | Radiologic examination, chest; single view | <1% | 1,823 | $4K |
| 83550 | <1% | 614 | $4K | |
| 97162 | <1% | 105 | $4K | |
| 86901 | <1% | 693 | $4K | |
| 82962 | <1% | 3,438 | $4K | |
| A9270 | Non-covered item or service | <1% | 751 | $4K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 229 | $4K |
| 98940 | <1% | 93 | $4K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 26 | $4K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 4,181 | $3K |
| 97810 | <1% | 119 | $3K | |
| 81001 | <1% | 4,083 | $3K | |
| 86803 | <1% | 149 | $3K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 675 | $3K |
| 70496 | <1% | 78 | $3K | |
| 87077 | <1% | 633 | $3K | |
| 96376 | <1% | 1,353 | $2K | |
| 83880 | <1% | 856 | $2K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 166 | $2K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,296 | $2K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 540 | $2K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 17 | $2K |
| 86780 | <1% | 120 | $2K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,240 | $2K |
| 87340 | <1% | 93 | $2K | |
| 74018 | <1% | 41 | $1K | |
| 87070 | <1% | 376 | $1K | |
| 85652 | <1% | 286 | $1K | |
| 97811 | <1% | 119 | $1K | |
| 83690 | <1% | 2,475 | $1K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 89 | $1K |
| 87186 | <1% | 499 | $1K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 67 | $1K |
| 70486 | <1% | 16 | $1K | |
| 82570 | <1% | 121 | $1K | |
| 82077 | <1% | 1,107 | $1K | |
| 82553 | <1% | 61 | $1K | |
| 80076 | <1% | 73 | $984.05 | |
| 84100 | <1% | 372 | $957.49 | |
| 82784 | <1% | 53 | $880.86 | |
| 82550 | <1% | 471 | $880.45 | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 32 | $831.99 |
| 90715 | <1% | 37 | $770.62 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 300 | $667.46 |
| 97802 | <1% | 13 | $639.42 | |
| 85730 | <1% | 1,276 | $595.83 | |
| 83605 | <1% | 1,237 | $505.75 | |
| 87205 | <1% | 350 | $505.05 | |
| 85379 | <1% | 706 | $497.72 | |
| 82746 | <1% | 108 | $493.83 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,183 | $488.11 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 104 | $478.16 |
| 81025 | <1% | 1,863 | $419.27 | |
| 85018 | <1% | 966 | $386.34 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,140 | $381.08 |
| 84132 | <1% | 1,095 | $357.64 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 338 | $341.13 |
| 99152 | <1% | 160 | $327.02 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 17 | $307.01 |
| 82043 | <1% | 35 | $260.00 | |
| 87040 | <1% | 505 | $259.38 | |
| 80069 | <1% | 27 | $238.95 | |
| 82375 | <1% | 866 | $229.75 | |
| 00840 | <1% | 64 | $214.92 | |
| 73560 | <1% | 14 | $179.31 | |
| 84703 | <1% | 537 | $161.36 | |
| 81003 | <1% | 70 | $158.79 | |
| 80320 | <1% | 13 | $156.29 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,322 | $123.93 |
| 83050 | <1% | 591 | $111.05 | |
| 84145 | <1% | 28 | $110.01 | |
| 84460 | <1% | 31 | $94.84 | |
| J2704 | Injection, propofol, 10 mg | <1% | 2,192 | $92.86 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,803 | $76.35 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 457 | $62.24 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,106 | $61.78 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,775 | $58.65 |
| 91300 | <1% | 1,213 | $53.55 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 803 | $40.49 |
| 00142 | <1% | 338 | $38.90 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,831 | $36.72 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,912 | $28.72 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,167 | $28.21 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 35 | $27.40 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 583 | $21.00 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 254 | $20.13 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,320 | $20.02 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 84 | $20.01 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 30 | $16.02 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 382 | $15.87 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 82 | $13.89 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 157 | $9.54 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 30 | $8.82 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,599 | $7.23 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 45 | $6.15 |
| 84450 | <1% | 14 | $5.98 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 97 | $5.74 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 397 | $4.68 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 23 | $4.00 |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 383 | $2.78 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 94 | $1.23 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 28 | $0.78 |
| 94760 | 0% | 778 | $0.00 | |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 40 | $0.00 |
| 88304 | 0% | 171 | $0.00 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 84 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 23 | $0.00 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 0% | 353 | $0.00 |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 0% | 65 | $0.00 |
| 80143 | 0% | 21 | $0.00 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 23 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 29 | $0.00 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 75 | $0.00 |
| 80179 | 0% | 20 | $0.00 | |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | 0% | 15 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 19 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLARAWAY, DENNIS (EXECUTIVE VP CHIEF FINANCE OFFICER)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.